Jaguar Health, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on July 28, 2017, by Jaguar Animal Health, Inc. (Jaguar). The report discloses a Regulation FD event regarding an investor call held on the same date. The primary focus of the filing is the shareholder approval of a merger between Jaguar and Napo Pharmaceuticals, Inc. (Napo), as well as updated financial guidance for Jaguar's product Mytesi.
Key Financial Metrics
The filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The only specific financial metric disclosed is a forward-looking revenue forecast.
- Mytesi Revenue Forecast: Approximately $7 million by April 2018.
Material Changes
The material change reported is the successful shareholder approval of the merger proposals between Jaguar and Napo Pharmaceuticals, Inc., which were previously announced and recommended by both boards.
Guidance, Outlook, and Management Commentary
Management provided updated guidance during the investor call, forecasting that Mytesi, a first-in-class anti-secretory agent for noninfectious diarrhea in adult HIV/AIDS patients, will generate approximately $7 million in revenue by April 2018. The filing notes that the merger with Napo has been approved by shareholders of both companies.
Investor Verification Checklist
- Verify the final closing date and terms of the merger between Jaguar and Napo Pharmaceuticals.
- Confirm the assumptions underlying the $7 million revenue forecast for Mytesi by April 2018.
- Review the combined balance sheet and liquidity position post-merger, as this 8-K does not contain current financial statements.
- Check for any subsequent filings regarding the integration of the two companies.